|
ELVN Enliven Therapeutics Inc 1672619 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-23,627,000.00 |
| Balance Sheet |
|
Current Assets
|
$463,137,000.00 |
|
Assets
|
$464,852,000.00 |
|
Current Liabilities
|
$11,487,000.00 |
|
Liabilities
|
$11,487,000.00 |
|
Equity
|
$453,365,000.00 |
|
Shares Out
|
60889655.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-19,291,000.00 |
|
Investing Cash Flow
|
$42,526,000.00 |
| Market Analysis |
Market Cap
|
$3,284,996,887.25 |
|
Price
|
$53.74 |
|
BVPS
|
7.45 |
|
PB
|
7.24 |
|
EPS
|
-0.38 |
|
FCF
|
$-19,291,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:21 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:16 |
|
| Apr |
May |
Jun |
| 2026-03-03 |
-0.48 |
|
|
2026-05-07 |
-0.38 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-13 |
-0.49 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-12 |
-0.32 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view ELVN documents filed with the SEC.
ELVN Filings
Clear
